New Zealand Clinical Research (NZCR) is New Zealand’s largest and leading early phase clinical research operation, with sites in Auckland, Hamilton, Wellington and Christchurch. They were formed in 2020 with the amalgamation of Auckland Clinical Studies (ACS) and Christchurch Clinical Studies Trust (CCST) who were established by Professor Richard Robson, one of the founding fathers of clinical research in New Zealand.
With over 20 years experience across both sites, NZCR:
Along with the experience of conducting over 600 studies with more than 15,000 participants dosed, NZCR has been instrumental in leading “world firsts” such as treatment for Hepatitis C, overseen by Professor Ed Gane, which has gone on to cure over 10 million HepC sufferers. Another was the world’s first ‘in-human’ trial of the Nobel prize-winning CRISPR/Cas9 gene editing technology, for the treatment of the deadly hereditary condition known as amyloidosis (FAP). This was also led by Professor Gane.
NZCR has a skilled, experienced team of clinical research professionals focusing on phase 1 and 2 trials, along with pharmacy and laboratory services. The clinical team is well supported by a central team that covers participant engagement, quality assurance, human resources and finance, all of whom are dedicated to NZCR’s purpose of advancing global health.